Compare · BHG vs ILMN
BHG vs ILMN
Side-by-side comparison of Bright Health Group Inc. (BHG) and Illumina Inc. (ILMN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BHG and ILMN operate in Medical Specialities (Health Care), so they compete in similar markets.
- ILMN is the larger of the two at $28.24B, about 16.9x BHG ($1.67B).
- ILMN has hit the wire 5 times in the past 4 weeks while BHG has been quiet.
- Both have 25 recent analyst ratings on file.
- Company
- Bright Health Group Inc.
- Illumina Inc.
- Price
- $14.94+43.65%
- $186.76-1.85%
- Market cap
- $1.67B
- $28.24B
- 1M return
- -
- +13.80%
- 1Y return
- -
- +97.03%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- 2000
- News (4w)
- 0
- 5
- Recent ratings
- 25
- 25
Bright Health Group Inc.
Bright Health Group, Inc., an integrated care delivery company, engages in the delivery and financing of health insurance plans in the United States. It operates in two segments, NeueHealth and Bright HealthCare. The company offers individual and family, Medicare, and employers insurance plans. It also operates 28 managed and affiliated risk-bearing primary care clinics. The company was formerly known as Bright Health Inc. and changed its name to Bright Health Group, Inc. in February 2021. Bright Health Group, Inc. was incorporated in 2015 and is based in Minneapolis, Minnesota.
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Latest BHG
- SEC Form SC 13G/A filed by Bright Health Group Inc. (Amendment)
- SEC Form SC 13D/A filed by Bright Health Group Inc. (Amendment)
- Bright Health Group Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Bright Health Group Adopts NeueHealth As Corporate Brand Name; Company's Common Stock Will Begin Trading Under The New Ticker Symbol "NEUE" On The New York Stock Exchange, Effective January 29, 2024
- Bright Health Group Adopts NeueHealth as Corporate Brand Name
- Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Bright Health Group Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- 12 Health Care Stocks Moving In Thursday's Intraday Session
- Bright Health Group Closes Sale Of Its California Medicare Advantage Business To Molina Healthcare, Reaffirms Expectation For Adj. EBITDA Profitability In 2024
- Bright Health Group Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
Latest ILMN
- Illumina expands Billion Cell Atlas program with new AI drug developers
- Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
- Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
- Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)
- Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)
- Bernstein resumed coverage on Illumina with a new price target
- Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)
- Director Skovronsky Daniel was granted 1,674 shares (SEC Form 4)
- SEC Form 3 filed by new insider Skovronsky Daniel
- Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits